Skip to content

Retatrutide Stacking Guide: Best Combinations & Protocols (2026)

From Peptidepedia, the trusted peptide wiki.

Stacking

Currently, there is limited published research on combining retatrutide with other peptides or compounds. Given its comprehensive triple-receptor mechanism, retatrutide functions as a standalone therapy that simultaneously addresses multiple metabolic pathways.

Theoretical considerations for researchers:

With other GLP-1 agonists: Not recommended due to overlapping mechanisms and increased risk of gastrointestinal adverse events.

With metformin: Clinical trials included participants on stable metformin therapy; the combination appeared well-tolerated.

With lifestyle interventions: The clinical trials incorporated dietary counseling and physical activity guidance, which should be considered complementary rather than optional.

Frequently Asked Questions

No. Retatrutide remains investigational and is not approved by the FDA or any regulatory agency. There are 19 clinical trials underway across the TRIUMPH, TRANSCEND, and SYNERGY programs. Key Phase 3 trials (TRIUMPH-1, -2, -3) are expected to read out by Q4 2026, with NDA submission projected for Q4 2026 to Q1 2027 and a PDUFA target action date of September to October 2027. The most likely approval window is late 2027 or early 2028.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389:514-526.
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544.
  3. Eli Lilly. What to know about retatrutide.
  4. Lilly's triple G agonist boasts 28.7% weight loss in Phase III trial. Clinical Trials Arena. 2025.
  5. Lilly's obesity triple pulls off 29% weight loss in trial. Pharmaphorum. 2025.
  6. Effects of retatrutide on body composition in people with type 2 diabetes. Lancet Diabetes Endocrinol. 2025.
  7. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist. PMC. 2024.
  8. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatohepatitis. Nature Medicine. 2024.
  9. The power of three: Retatrutide's role in modern obesity management. European Journal of Pharmacology. 2024.
  10. Retatrutide for Weight Loss: Availability, Dosage, and More. GoodRx. 2025.
  11. Eli Lilly. Lilly's retatrutide demonstrates significant improvements in blood sugar control and weight loss in adults with type 2 diabetes (TRANSCEND-T2D-1). Press release, March 2026.
  12. Marathe CS, et al. Retatrutide suppresses tumor growth in preclinical models of pancreatic and lung cancer. npj Metabolic Health and Disease. 2025.
  13. Retatrutide — A Game Changer in Obesity Pharmacotherapy: A Comprehensive Review. Biomolecules. 2025.
  14. Eli Lilly. Lilly's triple agonist retatrutide delivered weight loss averaging 28.7% in Phase 3 TRIUMPH-4 trial. Press release, December 2025.
  15. WADA Prohibited List 2026. World Anti-Doping Agency.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”